Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$479,876
-$651,085 QoQ
Shares Held
3,062
-58.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#902
of 1,603 holders
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bridgefront Capital, LLC holds $6,932,010 across 7 Drug Manufacturers - General names. NVS ranks #5 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
7,888 | $2,003,315 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
15,448 | $1,951,700 | |
| 3 | PFE |
Pfizer Inc
|
59,596 | $1,435,071 | |
| 4 | LLY |
ELI LILLY & Co
|
467 | $560,133 | |
| 5 | NVS |
Novartis AG
This page
|
3,062 | $479,876 | |
| 6 | GSK |
GSK plc
|
6,458 | $338,528 | |
| 7 | OGN |
Organon & Co.
|
12,067 | $163,387 |
All Filings in NVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $479,876 | 3,062 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,130,961 | 7,404 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $785,112 | 6,488 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,020,376 | 9,153 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $842,218 | 8,655 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||